100% Zufriedenheitsgarantie Sofort verfügbar nach Zahlung Sowohl online als auch als PDF Du bist an nichts gebunden
logo-home
Summary Psychology A-level Paper 3 Schizophrenia A* notes 12,99 €   In den Einkaufswagen

Zusammenfassung

Summary Psychology A-level Paper 3 Schizophrenia A* notes

 14 mal angesehen  0 mal verkauft
  • Kurs
  • Hochschule

You can set yourself up for success with notes that have been refined over two years to be as clear and effective as possible. I recently completed my Psychology A-levels with a predicted 3A*s, including a high score of 94/96 on Psychology Paper 3 in my mocks, using these notes. What these notes...

[ Mehr anzeigen ]

vorschau 2 aus 5   Seiten

  • 20. juni 2024
  • 5
  • 2023/2024
  • Zusammenfassung
avatar-seller
Classification and Diagnosis
Reliability and Validity of schizophrenia
Biological explanations for schizophrenia
Biological treatments for schizophrenia
Psychological explanations for schizophrenia
Psychological treatments for schizophrenia
The interactionist approach to schizophrenia
Managing Schizophrenia - Token Economies


Biological Explanations for Schizophrenia
Genetic similarities
Gotteman et al large scale family study →
Aunt 2%, sibling 9%, identical twin 48%
Share environment and genes - correlation

Candidate genes - polygenic inheritance coding for dopamine
Ripke et al - SCZ genetic makeup vs control - separate variations found
Aetiologically heterogeneous

OG hypothesis → hypERdopaminergia - high dopamine in subcortical areas (positive symptoms)
REVIVED → hypOdopaminergia - low dopamine in prefrontal cortex (negative symptoms)
Cortical hypOdopaminergia leads to supcortical hypERdopaminergia

Support → Tienari et al - adoptees in Finland w/ biological SCZ mother 6.9% chance
Hilker et al → concordance rates 33% MZ and 7% DZ - regardless of environment, genes significant

Limitation → environment significant. Morgan et al → birth complications and smoking THC cannabis in teen
years. Psychological risk e.g childhood trauma leads to vulnerability in mental health. Morkved → 67% SCZ at
least 1 childhood trauma vs 38% matched group with no psychotic issues. Genetics aren’t complete.

Support → Amphetamines increase dopamine worsening SCZ symptoms (Curran et al). Antipsychotics reduce
dopamine, reducing symptoms. Noll et al → dont work ⅓ w/ positive symptoms

Limitation → McCutcheon → post mortem showed raised glutamate levels in SCZ patients
Moghaddan and Javitt → link between glutamate and SCZ symptoms
Antipsychotics should not just focus on dopamine



Classification and Diagnosis

A01 thoughts and emotions are impaired and contact is lost with external reality. affects 1% of the population,
most common psychotic disorder, mainly men. the clinician uses a diagnostic manual for criteria fitting. American
DSM-5 (5 positive symptoms - 6 months symptoms) and European ICD-11 (2 or more symptoms - symptoms 1
month). subtypes dropped as inconsistent

A01 Positive - delusions and hallucinations
Negative - Alogia and Avolition

A03 Osorio - DSM-5 reliability 180 people. Interrater reliability +.97 and test retest +.92. Removed old criteria -
positive symptoms bizarre (subjective)

A03 Ethnocentric - cultural differences
Pinto and Jones - British African Caribbean 9x likely SCZ than British people
Luhmann interviewed 60 adults - Ghana, India, USA
Africans and Infians - positive experiences

, Us - negative experiences
Different meanings, discriminated against by cultural biassed system

A03 Gender bias
Fisher and Buchanan - men more diagnosed, ration 1.4:1
Genetically vulnerable or clinician affecting diagnosis - men overdiagnosed
Cotton et al - women closer, more support
Loosing custody
Underdiagnosis - receiving less treatment

A03 Symptom overlap - SCZ and BPD (delusions and avolition)
Ellason and Ross - DID more symptoms of SCZ than SCZ patients


Reliability and Validity of Schizophrenia

A01 Reliability - Interater - two clinicians reach the same conclusions with the same manual/criteria. Kappa score
of 1 (perfect agreement) and 0 (no agreement). 0.7 above is good. DSM-5 - Whaley - 0.11 and Reiger 0.46.
Manuals not reliable causing misdiagnosis/ missed diagnosis. Not accessing the right treatment/services. Test
retest - same conclusions reached at two different times.

A03 Osorio excellent reliability in DSM-5 for 180 individuals. Inter rater +.97 and test retest +.92. Improved
reliability by removing criteria that positive symptoms have to be ‘bizarre’ enough - subjective, disagreed
meaning.

A01 Reliability - Culture Bias - Pinto and Jones - British African Caribbean 9x likely diagnosed vs white british.
Those in their own countries aren't. Ethnocentric - not reliable as different diagnosis for different cultures, not
consistent.

A03 Luhmann interviewed 20 adults from Ghana, India and US about voices. Positive - playful, offering advice,
negative - violent and hateful. Culture impacts symptom experience. Shouldn’t be used to classify in other
cultures.

A01 Validity - Gender bias - Fisher and Buchanan - men more diagnosed 1.4:1. Cotton et al - women function
better, likely to work with good family relationships.

A03 Loring and Powell - overdiagnosis of males and underdiagnosis females - not enough service/treatment.
Gender influences diagnosis, male psychiatrist overdiagnosed men. Women don't want to lose custody.

A01 Symptom overlap - SCZ and BPD (delusions) - may not be two conditions. Hard to distinguish and diagnose.
Variations of the same condition?

A03 Ellason and Ross - DID more SCZ symptoms than SCZ patients. SCZ criteria invalid, not distinct from other
disorders, misdiagnosis likely.

Biological treatments for schizophrenia

A01 Typical antipsychotics - reduce positive symptoms
Antagonists bind to D2 - blocking neurotransmission
Kapur et al - 60-70% D2 receptors blocked - tardive dyskinesia
Chlorpromazine - initially dopamine increase then reduced production
Sedative calming - not just SCZ condition

A01 Atypical antipsychotics - reduce negative symptoms
Antagonists bind to D2 - blocking neurotransmission TEMPORARILY
Rapidly dissociate allowing normal transmission
No tardive dyskinesia
Clozapine - acts on dopamine, serotonin and glutamate receptors

Alle Vorteile der Zusammenfassungen von Stuvia auf einen Blick:

Garantiert gute Qualität durch Reviews

Garantiert gute Qualität durch Reviews

Stuvia Verkäufer haben mehr als 700.000 Zusammenfassungen beurteilt. Deshalb weißt du dass du das beste Dokument kaufst.

Schnell und einfach kaufen

Schnell und einfach kaufen

Man bezahlt schnell und einfach mit iDeal, Kreditkarte oder Stuvia-Kredit für die Zusammenfassungen. Man braucht keine Mitgliedschaft.

Konzentration auf den Kern der Sache

Konzentration auf den Kern der Sache

Deine Mitstudenten schreiben die Zusammenfassungen. Deshalb enthalten die Zusammenfassungen immer aktuelle, zuverlässige und up-to-date Informationen. Damit kommst du schnell zum Kern der Sache.

Häufig gestellte Fragen

Was bekomme ich, wenn ich dieses Dokument kaufe?

Du erhältst eine PDF-Datei, die sofort nach dem Kauf verfügbar ist. Das gekaufte Dokument ist jederzeit, überall und unbegrenzt über dein Profil zugänglich.

Zufriedenheitsgarantie: Wie funktioniert das?

Unsere Zufriedenheitsgarantie sorgt dafür, dass du immer eine Lernunterlage findest, die zu dir passt. Du füllst ein Formular aus und unser Kundendienstteam kümmert sich um den Rest.

Wem kaufe ich diese Zusammenfassung ab?

Stuvia ist ein Marktplatz, du kaufst dieses Dokument also nicht von uns, sondern vom Verkäufer juliettenivelle4. Stuvia erleichtert die Zahlung an den Verkäufer.

Werde ich an ein Abonnement gebunden sein?

Nein, du kaufst diese Zusammenfassung nur für 12,99 €. Du bist nach deinem Kauf an nichts gebunden.

Kann man Stuvia trauen?

4.6 Sterne auf Google & Trustpilot (+1000 reviews)

45.681 Zusammenfassungen wurden in den letzten 30 Tagen verkauft

Gegründet 2010, seit 14 Jahren die erste Adresse für Zusammenfassungen

Starte mit dem Verkauf
12,99 €
  • (0)
  Kaufen